4 news items
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
OCUP
VTRS
10 May 24
, the LYNX-2 Phase 3 registration study, the benefits, uses, and side effects of PS treatment, ongoing discussions with the FDA regarding various of our
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
ABNB
AKAM
APP
9 May 24
benefits rose from 209,000 to 231,000 in the week ending May 4, surpassing market expectations of 210,000 and reaching
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
VTRS
27 Mar 24
; the possibility that Viatris may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
VTRS
11 Mar 24
for the payment of $16,000,000.00 in cash for the benefit of the Settlement Class, and (ii
- Prev
- 1
- Next